Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share. Please see the attached notification form for further information. Jon Olav Ødegård, CEO of Hofseth BioCare ASAPhone: +47 936 32 966E-mail: joo@hofsethbiocare.no This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 arti
In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to NOK 18m in the same period last year. The finished goods business delivered record fourth quarter and Full Year revenue and cash margin, with revenue at +68 %, NOK 31.7m, compared to 18.8m in the same period in 2021, and the fourth quarter alone delivering NOK 10.7m, compared to 3.7m last year. HBC h
Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider of Hofseth BioCare ASA. After the transaction, Ødegård Prosjekt AS holds 2,964,039 shares, including 860,000 shares held indirectly through ownership in Brilliant Invest AS. Mr. Ødegård also holds 1,000,000 share options, totalling 4,034,039 shares and share options corresponding to approx. 1.0 % o